19.1 and 24.2, compared with 14.4 and 21.5, respectively, in the adolescent males.
By week 12, in the adult males there was a 62.3% and 59.5% change in inflammatory and noninflammatory lesion counts from baseline (LS mean) with tazarotene 0.045% lotion, compared with 49.4% (P=0.001) and 49.5% (P=0.016) in the adolescent males (Figures 2 and 3). Efficacy differences between the adult and adolescent males were significant from week 4.
At baseline, the mean scores for Self-Perception, Role-Emotional, Role-Social, and Acne Symptoms in those subjects subsequently treated with tazarotene 0.045% lotion were higher (ie, better QoL) in the adolescent males: 27.2, 27.0, 23.8, and 22.5 compared with 20.1, 21.3, 18.1, and 19.2, respectively, in the adult males. By week 12 the absolute change from baseline in Self-Perception, Role-Emotional, Role-Social and Acne Symptom domains were 3.0, 1.7, 1.8, and 3.9, respectively, in